CME Funding Not Reportable Under Sunshine Law, But Bias Debate Continues
Executive Summary
ACCME report finds “no evidence to support or refute” belief that commercial support creates commercial bias in CME activities.
You may also be interested in...
Sunshine Website Goes Live With Some Context Sought By Industry
CMS releases data on $3.5 billion worth of payments made by drug and device companies to physicians and teaching hospitals in the last five months of 2013; an additional 199,000 payment records were not disclosed.
CME Programs Endure As Industry Funding, Number Of Providers Declines
Accreditation Council for Continuing Medical Education reports that commercial support for CME activities declined in 2011 but the number of activities increased 3.8%; more than 20 million participated in CME programs.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.